These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32287579)

  • 1. Chapter 4 Picornavirus infections.
    Perspect Med Virol; 1985; 1():127-186. PubMed ID: 32287579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of human picornaviruses by nucleic acid probes.
    Hyypiä T
    Mol Cell Probes; 1989 Dec; 3(4):329-43. PubMed ID: 2559319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An RNA replication-center assay for high content image-based quantifications of human rhinovirus and coxsackievirus infections.
    Jurgeit A; Moese S; Roulin P; Dorsch A; Lötzerich M; Lee WM; Greber UF
    Virol J; 2010 Oct; 7():264. PubMed ID: 20937137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Adjuvanted-Whole Inactivated Virus and Live-Attenuated Virus Vaccines against Challenge with Contemporary, Antigenically Distinct H3N2 Influenza A Viruses.
    Abente EJ; Rajao DS; Santos J; Kaplan BS; Nicholson TL; Brockmeier SL; Gauger PC; Perez DR; Vincent AL
    J Virol; 2018 Nov; 92(22):. PubMed ID: 30185589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of anti-picornavirus therapies.
    Barnard DL
    Curr Pharm Des; 2006; 12(11):1379-90. PubMed ID: 16611122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Old and new prescriptions for infectious diseases and the newest recipes for biomedical products in plants].
    Koprowski H
    Arch Immunol Ther Exp (Warsz); 2002; 50(6):365-9. PubMed ID: 12549429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Picornavirus non-structural proteins as targets for new anti-virals with broad activity.
    Norder H; De Palma AM; Selisko B; Costenaro L; Papageorgiou N; Arnan C; Coutard B; Lantez V; De Lamballerie X; Baronti C; Solà M; Tan J; Neyts J; Canard B; Coll M; Gorbalenya AE; Hilgenfeld R
    Antiviral Res; 2011 Mar; 89(3):204-18. PubMed ID: 21236302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divergent Requirement for a DNA Repair Enzyme during Enterovirus Infections.
    Maciejewski S; Nguyen JH; Gómez-Herreros F; Cortés-Ledesma F; Caldecott KW; Semler BL
    mBio; 2015 Dec; 7(1):e01931-15. PubMed ID: 26715620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Basis of Coronavirus Virulence and Vaccine Development.
    Enjuanes L; Zuñiga S; Castaño-Rodriguez C; Gutierrez-Alvarez J; Canton J; Sola I
    Adv Virus Res; 2016; 96():245-286. PubMed ID: 27712626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination against acute respiratory virus infections and measles in man.
    Osterhaus AD; de Vries P
    Immunobiology; 1992 Feb; 184(2-3):180-92. PubMed ID: 1587542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reverse Genetics Approaches for the Development of Influenza Vaccines.
    Nogales A; Martínez-Sobrido L
    Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28025504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis.
    Pliaka V; Kyriakopoulou Z; Markoulatos P
    Expert Rev Vaccines; 2012 May; 11(5):609-28. PubMed ID: 22827246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rhinovirus identification by BglI digestion of picornavirus RT-PCR amplicons.
    Papadopoulos NG; Hunter J; Sanderson G; Meyer J; Johnston SL
    J Virol Methods; 1999 Jul; 80(2):179-85. PubMed ID: 10471027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study.
    Van Damme P; De Coster I; Bandyopadhyay AS; Revets H; Withanage K; De Smedt P; Suykens L; Oberste MS; Weldon WC; Costa-Clemens SA; Clemens R; Modlin J; Weiner AJ; Macadam AJ; Andino R; Kew OM; Konopka-Anstadt JL; Burns CC; Konz J; Wahid R; Gast C
    Lancet; 2019 Jul; 394(10193):148-158. PubMed ID: 31174831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-Generation Live-Attenuated Candid#1 Vaccine Virus Resists Reversion and Protects against Lethal Junín Virus Infection in Guinea Pigs.
    Gowen BB; Hickerson BT; York J; Westover JB; Sefing EJ; Bailey KW; Wandersee L; Nunberg JH
    J Virol; 2021 Jun; 95(14):e0039721. PubMed ID: 33952638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antivirals and vaccines for Enterovirus A71.
    Lin JY; Kung YA; Shih SR
    J Biomed Sci; 2019 Sep; 26(1):65. PubMed ID: 31481071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized placebo-controlled trial.
    Crothers JW; Ross Colgate E; Cowan KJ; Dickson DM; Walsh M; Carmolli M; Wright PF; Norton EB; Kirkpatrick BD
    Vaccine; 2022 Apr; 40(19):2705-2713. PubMed ID: 35367069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case for developing antiviral drugs against polio.
    Collett MS; Neyts J; Modlin JF
    Antiviral Res; 2008 Sep; 79(3):179-87. PubMed ID: 18513807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.